System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural Ppublish 13 citations

PubMed: 37812652 DOI: 10.1158/1078-0432.CCR-23-2187

Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma.

Clin Cancer Res 30(5):1022-1037

Authors: Brian Mooney, Gian Luca Negri, Taras Shyp, Alberto Delaidelli, Hai-Feng Zhang, Sandra E Spencer Miko, Amber K Weiner, Alexander B Radaoui, Rawan Shraim, Michael M Lizardo, Christopher S Hughes, Amy Li, Amal M El-Naggar, Melanie Rouleau, Wei Li, Dimiter S Dimitrov, Raushan T Kurmasheva, Peter J Houghton, Sharon J Diskin, John M Maris, Gregg B Morin, Poul H Sorensen

Affiliations

  • Canada's Michael Smith Genome Sciences Centre, BC Cancer Research Institute, Vancouver, British Columbia, Canada.
  • Department of Molecular Oncology, BC Cancer Research Institute, Vancouver, British Columbia, Canada.
  • Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • Division of Infectious Diseases, Department of Medicine, Center for Antibody Therapeutics, University of Pittsburgh Medical School, Pittsburgh, Pennsylvania.
  • Greehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, Texas.
  • Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
  • Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.

Abstract

PURPOSE

Ewing sarcoma is the second most common bone sarcoma in children, with 1 case per 1.5 million in the United States. Although the survival rate of patients diagnosed with localized disease is approximately 70%, this decreases to approximately 30% for patients with metastatic disease and only approximately 10% for treatment-refractory disease, which have not changed for decades. Therefore, new therapeutic strategies are urgently needed for metastatic and refractory Ewing sarcoma.

EXPERIMENTAL DESIGN

This study analyzed 19 unique Ewing sarcoma patient- or cell line-derived xenografts (from 14 primary and 5 metastatic specimens) using proteomics to identify surface proteins for potential immunotherapeutic targeting. Plasma membranes were enriched using density gradient ultracentrifugation and compared with a reference standard of 12 immortalized non-Ewing sarcoma cell lines prepared in a similar manner. In parallel, global proteome analysis was carried out on each model to complement the surfaceome data. All models were analyzed by Tandem Mass Tags-based mass spectrometry to quantify identified proteins.

RESULTS

The surfaceome and global proteome analyses identified 1,131 and 1,030 annotated surface proteins, respectively. Among surface proteins identified, both approaches identified known Ewing sarcoma-associated proteins, including IL1RAP, CD99, STEAP1, and ADGRG2, and many new cell surface targets, including ENPP1 and CDH11. Robust staining of ENPP1 was demonstrated in Ewing sarcoma tumors compared with other childhood sarcomas and normal tissues.

CONCLUSIONS

Our comprehensive proteomic characterization of the Ewing sarcoma surfaceome provides a rich resource of surface-expressed proteins in Ewing sarcoma. This dataset provides the preclinical justification for exploration of targets such as ENPP1 for potential immunotherapeutic application in Ewing sarcoma. See related commentary by Bailey, p. 934.

MeSH

Cells, Sarcoma, Ewing, Neoplasms, Sarcoma, Cell Line, Membrane Proteins, Therapeutics, Proteome

Cited by